ArticleFrontiers in medicine2025
Examining the mediating function of SIRI in the association between LC9 and chronic obstructive pulmonary disease.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a major contributor to early mortality, high overall mortality rates, and significant healthcare costs. Based on the Life's Essential 8 (LE8), Life's Crucial 9 (LC9) is a new cardiovascular health evaluation instrument that also includes a mental health examination, while the systemic inflammation response index (SIRI) is an emerging biomarker of systemic inflammation. The purpose of this study is to look at the link between LC9 and COPD and how SIRI may play a mediating function in it. Methods: Data from 25,721 U.S. participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018 were used in a cross-sectional study. To investigate the relationship between COPD and LC9, multivariable logistic regression, restricted cubic splines (RCS), and subgroup analysis were used. Furthermore, a mediation study was conducted to evaluate SIRI's possible involvement in the connection between LC9 and COPD. Results: It consisted of 25,721 persons in all, 1,257 of whom had COPD. When multiple covariates were taken into account, logistic regression analysis showed that a 28% decrease in the prevalence of COPD was linked to every 10-point increase in LC9 (OR = 0.72, 95% CI: 0.67, 0.77), while a 1.17-fold increase in the prevalence of COPD was linked to each unit increase in SIRI (OR = 1.17, 95% CI: 1.10, 1.25). When LC9 and SIRI were divided into tertiles, similarities were seen (P for trend <0.001). A linear negative correlation between LC9 and the prevalence of COPD was shown using RCS analysis. Also, mediation analysis indicated that SIRI mediated 1.64% of the link between LC9 and COPD ( Conclusion: As shown by this study, LC9 and COPD display a substantial negative connection, which is largely mediated by SIRI. These results demand more investigation because they show a possible connection between cardiovascular health and COPD and offer fresh perspectives on the role systemic inflammation plays in this relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.